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Abstract
Background:  Antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus aureus
(MRSA)  and vancomycin-resistant enterococcus (VRE,  are  an  increasing  problem world-wide,
causing intractable wound infections. Complex phytochemical extracts such as tea tree oil and
eucalypt-derived formulations have been shown to have strong bactericidal activity against MRSA
in vitro. Polytoxinol (PT) antimicrobial, is the trade name of a range of antimicrobial preparations
in solution, ointment and cream form.
Methods:  We report the first use of this drug, administered percutaneously, via calcium sulphate
pellets (Osteoset,TM), into bone, to treat an intractable MRSA infection of the lower tibia in an
adult male.
Results and Discussion:  Over a three month period his symptoms resolved with a healing
response on x-ray and with a reduced CRP.
Background
Antibiotic-resistant bacteria such as methicillin-resist-
ant Staphylococcus aureus (MRSA) and vancomycin-re-
sistant enterococcus (VRE), are an increasing problem
world-wide, causing intractable wound infections [1,2].
Complex phytochemical extracts such as tea tree oil and
eucalypt-derived formulations [3] have been shown to
have strong bactericidal activity against MRSA in vitro.
Polytoxinol™ (PT) antimicrobial, is the trade name of a
range of antimicrobial preparations in solution, oint-
ment and cream form. We report the first use of this
drug, administered percutaneously, via calcium sulphate
pellets (Osteoset™), into bone, to treat an intractable
MRSA infection of the lower tibia in an adult male.
Once antibiotics fail, treatment options are limited to de-
bridement, removal of hardware, or amputation. The ac-
tive ingredients are compounded Phytochemicals
(Lemongrass, Eucalyptus, Melaleuca, Clove, Thyme as
well as B.H.T. (Butylated Hydroxy Toluene), Triclosan
(0.3%) and 95 undematured ethano (69.7%).
Methods
On 20/3/97, a 49 year-old man sustained an open frac-
ture of his left tibia (Gustillo-Anderson Classification
Grade 3 C) after falling and being run over by a golfcart.
He underwent debridement and insertion of an in-
tramedullary nail (IM). Two months later he required a
free-flap to the lower tibia, re-positioning of the IM nail
and a femoral-popliteal bypass graft. Eight months later,
he required debridement of the flap and fifteen months
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later debridement of an infective focus of the lower tibia.
The fracture and soft tissues later healed but he devel-
oped chronic osteomyelitis of the lower tibia (with MR-
SA) requiring long term antibiotic treatment with
flucloxacillin (one gram orally six hourly) and dicloxacil-
lin (one gram orally six hourly). (Fig 1). He had previous-
ly received four courses of intravenous flucloxacillin (one
gram six hourly) and intravenous dicloxacillin (one gram
six hourly) over the previous two years. His lower leg
continued to swell and cause pain, especially at night
with significant disability, making it impossible to return
to employment as a chef. After repeated debridement
and further intravenous antibiotics, as a last resort, am-
putation was considered. He then came under the care of
Dr Eugene Sherry and requested application of PT to the
infected bone area to save his limb. Antibiotics had been
discontinued two months prior to surgery and have re-
mained so. The ESR = 4 (normal <11 mm/hr), and the
CRP = 21.9 (normal < 10 mg/l). Written permission was
obtained. On December 8, 2000, on an emergency basis
(as he was in severe pain with a flare-up), he was taken to
the OR and via a 3 cm percutaneous incision medial to
the anterior tibial flap, the lower tibia was drilled (4.5
mm), curetted, washed-out with 4,000 ml normal saline
and packed with Osteoset Pellets™ soaked in 3 ml of PT
liquid. A funnel was used to insert the beads. A catheter
was left in situ for further administration of the antisep-
tic over the following 48 hours (one ml per day). At three
months, the wound has healed, symptoms have resolved,
he feels better, his ESR = 14, CRP = 12, wound cultures
were clear and a plain x-ray shows resolution of infective
process with incorporation of the bone graft. (Fig. 2)
Discussion
Antibiotic-resistant Gram-positive cocci, especially MR-
SA, causing wound infections are of great concern as they
cause increased mortality rates, hospitalisation and
longer treatment to discharge times [4]. This is especially
so in orthopaedic surgery with the use of internal fixation
and prosthetic devices as bacteria compete with host
cells to colonise these foreign surfaces [5]. Aggressive
prophylaxis with antibiotics and optimised surgical
strategies can reduce the frequency of MRSA infections
[2,5], although increasing the cost of surgery.
Figure 1
Pre-operative x-ray of lower tibia and ankle showing chronic
osteomyelitis with cyst formation.
Figure 2
X-Ray at 3 months showing resolution of infective process
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PT is a complex chemical mixture and the biological ac-
tivity of its major components, tea tree oil and eucalyp-
tus, [6,7] have been described. A recent paper by
Anderson and Fennessy reviewed and concluded that
there was compelling in vitro evidence of the effective-
ness of tea tree oil against MRSA; here we add a clinical
case [3]. This case report describes a cheap, simple tech-
nique as a possible alternative to long-term systemic an-
tibiotic therapy. Here it was administered
percutaneously over calcium sulphate pellets and then
topped-up via a catheter. It may also be used topically.
The beads were used as a vehicle for PT and as a bone
graft. More extensive case studies or a randomised con-
trolled trial are now suggested.
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